Shanghai BDgene Technology completed a $9 million Series A round to develop its mRNA delivery platform, a viroid-like particle delivery system of mRNA. BDgene, a clinical stage company, uses the technology to deliver CRISPR/Cas9 mRNA, which provides ...

 


ChinaBio® Weekly Update

Contents


BDgene Completes $9 Million Round for CRISPR/Cas9 mRNA Candidates

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai BDgene Technology completed a $9 million Series A round to develop its mRNA delivery platform, a viroid-like particle delivery system of mRNA. BDgene, a clinical stage company, uses the technology to deliver CRISPR/Cas9 mRNA, which provides safe and controllable gene editing in vivo, according to the company. BDgene's lead product is BD111, a CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered via corneal injection in patients with refractory herpetic viral keratitis, which has been approved for a six patient clinical trial in China. More details....

Share this with colleagues:

     
 

Innovent Reports Positive Data from Phase III Tyvyt Trial in NSCLC

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Innovent Biologics of Suzhou reported positive data from a Phase III trial of its anti-PD-1 drug, Tyvyt®, as a second line therapy for patients with non-small cell lung cancer. Patients who received Tyvyt® experienced a statistically significant improvement in overall survival compared to those who received docetaxel. Currently, Innovent has three Tyvyt® NDAs under review in China. In addition, the company is conducting more than 20 clinical trials of Tyvyt® in a variety of cancer indications. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

     
 

LintonPharm Starts China Trial of Candidate for Bladder Cancer

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

LintonPharm, a Guangzhou biopharma, was approved to start a China Phase I/II clinical trial of catumaxomab to treat recurrent Non-Muscle-Invasive Bladder Cancer (NMIBC). The trial will enroll patients whose tumors have recurred due to Bacillus Calmette-Guerin (BCG) vaccine failure. In 2020, LintonPharm started a China Phase III trial of catumaxomab. an immunotherapy, in patients with advanced gastric cancer. LintonPharm develops innovative T cell engaging bispecific antibodies, aiming to turn malignant cancers into manageable or curable diseases. More details....

Share this with colleagues:

     
 

Junshi's PD-1 Approved for Third Indication in China, Bladder Cancer

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai Junshi Bio announced China's NMPA approved a third indication for the company's PD-1 drug. Toripalimab is now approved as a second-line therapy for locally advanced or metastatic urothelial carcinoma in patients who failed platinum-based chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum chemotherapy. Previously, toripalimab was approved as a second-line treatment for metastatic melanoma and a third-line therapy for nasopharyngeal carcinoma. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:

     
 

Gracell Reports Positive Data from Trial of Off-the Shelf CAR-T Candidate

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Gracell Biotech, a Suzhou cell therapy company, reported positive results from a China Phase I trial of its allogeneic CAR-T candidate. GC027 targets CD7. It was administered to adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) who had previously been treated with a median of six therapies. A single infusion of GC027 at one of three dosing levels produced a complete remission in all six patients. In the future, Gracell plans to test GC027 in global markets for T-All and other cancers as well. More details...

Stock Symbol: (NDQQ: GRCL)

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


 Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC

 

 


 


Safely Unsubscribe ArchivesPreferencesContactSubscribePrivacy